(Q47803013)

5 February 2018

title

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides (English)

1 reference

5 February 2018

author name string

M N Saleh

1

1 reference

5 February 2018

C F LeMaistre

2

1 reference

5 February 2018

T M Kuzel

3

1 reference

5 February 2018

F Foss

4

1 reference

5 February 2018

L C Platanias

5

1 reference

5 February 2018

G Schwartz

6

1 reference

5 February 2018

M Ratain

7

1 reference

5 February 2018

A Rook

8

1 reference

5 February 2018

C O Freytes

9

1 reference

5 February 2018

F Craig

10

1 reference

5 February 2018

J Reuben

11

1 reference

5 February 2018

M W Sams

12

1 reference

5 February 2018

J C Nichols

13

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 1998

1 reference

5 February 2018

Journal of the American Academy of Dermatology

published in

1 reference

5 February 2018

volume

39

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

63-73

1 reference

5 February 2018

The crystal structure of diphtheria toxin

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Effect of pH on the conformation of diphtheria toxin and its implications for membrane penetration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Recombinant toxins as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Lymphocyte populations and TAC-antigen in diffuse B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

T cell growth factor receptors. Quantitation, specificity, and biological relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Cutaneous T-cell lymphoma (mycosis fungoides)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Epidemiology and clinical manifestations of cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Treatment of leukemia patients with T101 ricin A chain immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Immunotoxin therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Monoclonal antibody analysis of diphtheria toxin—I. Localization of epitopes and neutralization of cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970403-7

7 January 2021

10.1016/S0190-9622(98)70403-7

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

9674399

1 reference

5 February 2018